Phase II Study of Stereotactic Body Radiotherapy SBRT Plus Standard Treatment for Patients With Limited Metastatic Breast or Lung Cancer

What this Trial Is About

Researchers are evaluating whether stereotactic body radiotherapy SBRT given to all sites of disease in patients with 1 to 5 metastatic cancer lesions can delay the progression of their condition. This study focuses on patients with metastatic breast cancer or non-small cell lung cancer, aiming to see if adding SBRT to standard treatments can extend the time before the disease worsens. Participants are assigned to one of two groups. One group receives the standard care treatment determined by their oncologist, which may include chemotherapy, targeted therapy, immunotherapy, or hormonal therapy. The other group receives SBRT targeted to all visible metastatic sites, with radiation doses tailored by the radiation oncologist, alongside standard systemic therapies. SBRT is delivered concurrently to all metastatic sites, and after completion, standard care continues. Radiation doses vary depending on the location of metastases, with specific dosing recommendations for lung and bone metastases. Throughout the study, participants will be monitored for how long their cancer remains stable without worsening, with follow-up lasting up to two years to assess progression-free survival and overall survival. Researchers will perform imaging studies and clinical assessments to measure disease status. Patients may continue systemic therapy during SBRT as advised by their doctors. Safety and effectiveness of the combined treatments will be carefully tracked during the study period.

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease